Last reviewed · How we verify
Citrate 4%
Citrate 4% acts as an anticoagulant by chelating calcium ions, preventing blood clotting in extracorporeal circuits such as dialysis and apheresis systems.
Citrate 4% acts as an anticoagulant by chelating calcium ions, preventing blood clotting in extracorporeal circuits such as dialysis and apheresis systems. Used for Anticoagulation in hemodialysis and hemofiltration, Anticoagulation in apheresis and extracorporeal blood purification procedures.
At a glance
| Generic name | Citrate 4% |
|---|---|
| Also known as | there is no other intervention names |
| Sponsor | Centre Hospitalier Universitaire Dijon |
| Drug class | Anticoagulant (chelating agent) |
| Target | Ionized calcium (Ca2+) |
| Modality | Small molecule |
| Therapeutic area | Hematology / Nephrology |
| Phase | FDA-approved |
Mechanism of action
Citrate binds ionized calcium in the blood, reducing the concentration of free calcium below the threshold required for the coagulation cascade to proceed. This prevents thrombosis in extracorporeal circuits while maintaining systemic coagulation through calcium metabolism and citrate clearance. The anticoagulant effect is localized to the circuit and reversible as citrate is metabolized by the liver.
Approved indications
- Anticoagulation in hemodialysis and hemofiltration
- Anticoagulation in apheresis and extracorporeal blood purification procedures
Common side effects
- Hypocalcemia (systemic)
- Metabolic alkalosis
- Hypernatremia
- Citrate accumulation (in hepatic dysfunction)
Key clinical trials
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery (PHASE2)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Citrate 4% CI brief — competitive landscape report
- Citrate 4% updates RSS · CI watch RSS
- Centre Hospitalier Universitaire Dijon portfolio CI